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Abstract
Background: The ability of subjects to respond to nutritional challenges can reflect the flexibility of their biological system.
Nutritional challenge tests could be used as an indicator of health status but more knowledge on metabolic and immune
responses of different subjects to nutritional challenges is needed. The aim of this study was to compare the responses to
high-fat challenges varying in fat type in subjects with different metabolic risk phenotypes.
Methodology/Principal Findings: In a cross-over design 42 men (age 50–70 y) consumed three high-fat shakes containing
saturated fat (SFA), monounsaturated fat (MUFA) or n-3 polyunsaturated (PUFA). Men were selected on BMI and health
status (lean, obese or obese diabetic) and phenotyped with MRI for adipose tissue distribution. Before and 2 and 4 h after
shake consumption blood was drawn for measurement of expression of metabolic and inflammation-related genes in
peripheral blood mononuclear cells (PBMCs), plasma triglycerides (TAG), glucose, insulin, cytokines and ex vivo PBMC
immune response capacity. The MUFA and n-3 PUFA challenge, compared to the SFA challenge, induced higher changes in
expression of inflammation genes MCP1 and IL1b in PBMCs. Obese and obese diabetic subjects had different PBMC gene
expression and metabolic responses to high-fat challenges compared to lean subjects. The MUFA challenge induced the
most pronounced TAG response, mainly in obese and obese diabetic subjects.
Conclusion/Significance: The PBMC gene expression response and metabolic response to high-fat challenges were affected
by fat type and metabolic risk phenotype. Based on our results we suggest using a MUFA challenge to reveal differences in
response capacity of subjects.
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Introduction
In the western world food is generally continuously available
and most of the day is spent in the postprandial state. Food intake
can elicit a transient metabolic and low inflammatory response,
especially when high fat is consumed [1,2,3]. The magnitude of
this response reflects the ability of the biological system to
adequately respond to nutrient intake. The presence of metabolic
risk phenotypes such as obesity and type 2 diabetes might affect
this ability as shown by elevated postprandial triglyceride
concentrations in these subjects, in addition to metabolic
abnormalities and chronic inflammation in the fasting state
[4,5,6,7,8]. Not only the presence of overall obesity, but also
body fat distribution, i.e. increased intra-abdominal (visceral)
adipose tissue, might affect the metabolic condition and the
postprandial triglyceride response [9].
Elevated postprandial triglyceride concentrations are considered
as risk factors for cardiovascular disease and were higher
associated with cardiovascular events compared to fasting triglyc-
eride concentrations [10,11]. The response to a nutritional
challenge test might thus be considered as a better biomarker of
health status than fasting measures, since this will reflect a person’s
metabolic flexibility and capacity to adapt [12,13]. A widely
applied example of a nutritional challenge test is the oral glucose
tolerance test for measuring glucose clearance capacity. Nutri-
tional challenge tests might be useful to detect small changes in
health status, which could be of major importance in early
detection and prevention of disease, but could also be used to test
the effectiveness of (nutritional) interventions [12,14]. However, at
the moment relatively little is known about responses of different
types of subjects to nutritional challenges such as a high-fat load
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which makes it difficult to use the response to challenges as
biomarkers for characterization of health status.
Postprandial meal studies showed that the type of fat consumed
could affect the metabolic and inflammatory response
[2,15,16,17,18,19] and gene expression responses in circulating
peripheral blood mononuclear cells (PBMCs) [18]. PBMCs are
immune cells that have been shown to be metabolically active
[20], moreover, gene expression profiles of PBMCs were shown to
reflect metabolic disease state and changes in nutrient intake
which makes these cells an interesting target to investigate
responses to nutritional challenges in different subjects [21,22,23].
The objective of this study is to characterize the PBMC,
metabolic and immune response to high-fat challenges in subjects
with different metabolic risk phenotypes. Responses to different
types of fat (SFA, MUFA and n-3 PUFA) were compared in order
to reveal which type of fat may be best used in future high-fat
challenges to test response capacity of subjects.
Methods
The protocol for this trial and CONSORT checklist are
available as supporting information (Protocol S1 and Checklist
S1).
Study Population and Eligibility Criteria
Male Caucasian volunteers aged 50–70 years participated in the
study. The study population consisted of three groups; 1) lean
subjects, 2) obese subjects and 3) obese type 2 diabetic subjects.
Subjects were excluded if they were vegetarian, regular tobacco
smoker, allergic to dairy products or fish oil, current or recent user
of fish oil supplements, consumed more than four times fish/wk,
had an unstable body weight, used antibiotics or anti-inflamma-
tory medication or had a long-term medical condition that could
interfere with the study outcome. Lean and obese subjects were
excluded when using cholesterol-lowering medication; and lean
subjects were excluded when using blood pressure lowering
medication. Obese diabetic subjects were all diagnosed with
diabetes mellitus in the past, and did not use insulin and/or
thiazolidinediones. During a screening visit an oral glucose
tolerance test (OGTT) was performed and fasting urinary glucose
concentration was measured in healthy subjects to exclude the
presence of (unknown) diabetes mellitus (fasting blood glucose
,7 mmol/L, 2 hr after OGTT ,7.8 mmol/L). Subjects were
informed about the design and purpose of the study and all
subjects provided written informed consent. The Medical Ethical
Committee of Wageningen University (the Netherlands) approved
the study and the study was registered at clinicaltrials.gov as
NCT00977262. The study was conducted according to the
principles of the declaration of Helsinki and in accordance with
the Medical Research Involving Human subject Act.
Sample size was determined based on the sample size in a
comparable study with lean male subjects in which differences in
PBMC gene expression after consumption of three different high
fat shakes were detected [18].
Study Design
All subjects consumed three high-fat shakes enriched with SFA,
MUFA or n-3 PUFA in a crossover design, on three different days
with at least one week between each study day. Participants in
each subject group were randomly allocated to one of the six
possible sequences of shake consumption. The possible sequences
were equally distributed over the participants within a subject
group. A research assistant generated the random allocation
sequence and assigned the subjects to the interventions. Shakes
were given a letter code and both subjects and researchers were
blinded to the intervention.
The evening before the study day, subjects consumed an
identical low-fat meal and were not allowed to eat or drink
anything after 8 pm except water. The next morning, subjects
came to Wageningen University, the Netherlands, and a fasting
blood sample was collected. Blood was drawn into EDTA-
containing tubes for plasma isolation and into BD Vacutainer Cell
Preparation Tubes containing sodium citrate (Becton Dickinson,
Breda, Netherlands) for PBMC isolation. After the first blood
sample subjects received a high-fat shake, which they had to
consume within 15 min. Blood samples were collected 2 h and
4 hours after consumption of the high-fat shake. During a study
day, subjects were physically inactive and did not eat or drink
anything except water.
Shake Composition
All high-fat shakes were isocaloric and differed only in fat
composition. The shakes contained low-fat yoghurt, low-fat milk,
strawberry flavour, 7.5 g of sugar and 95 g of the test fat. The SFA
shake contained 95 g palm oil (Research Diet Services BV, Wijk
bij Duurstede, The Netherlands) and the MUFA shake contained
95 g high-oleic acid sunflower oil (Aldoc BV, Schiedam, The
Netherlands). The n-3 PUFA shake contained 40 g palm oil and
55 g Marinol D-40 (Lipid Nutrition, Wormerveer, The Nether-
lands), of which 40% was docosahexanoic acid (DHA). Vitamin E
(165 mg Tocoblend L50, Vitablend, Wolvega, The Netherlands)
was added to Marinol D-40 by the manufacturer to prevent
oxidation. The same amount of vitamin E was added to the SFA
and MUFA shakes. The macronutrient composition of the shakes
was calculated based on the database of the Dutch Nutrient
Databank and shown in table 1.
Primary Study Outcomes
The primary outcomes of the study were postprandial gene
expression changes of immune-related genes (IL1b, IL8, Mono-
cyte chemotactic protein 1 (MCP1), nuclear factor of kappa light
polypeptide gene enhancer in B-cells 1 (NFkB1), TNFa) and
lipid metabolism related genes (ATP-binding cassette sub-family
A member 1 (ABCA1), pyruvate dehydrogenase kinase isozyme
4 (PDK4), sterol regulatory element binding transcription factor
1 (SREBP1), LDL receptor (LDLr), liver X receptor alpha
Table 1. Macronutrient composition of the fat shakes.
SFA shake MUFA shake
n-3 PUFA
shake
Energy (kJ) 4074 4074 4074
Energy (kcal) 987 987 987
Protein (g) 10 10 10
Carbohydrates (g) 22 22 22
Fat (g) 95 95 95
SFA (g) 51 8 32
MUFA (g) 37 79 25
PUFA (g) 6 8 38
EPA (g) – – 3
DHA (g) – – 23
Vitamin E (mg) 165 165 165
doi:10.1371/journal.pone.0041388.t001
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(LXRa), cytochrome P450 family 27 subfamily A polypeptide 1
(CYP27A1) in PBMCs. These genes were selected because we
previously showed that their expression was affected by high-fat
consumption [18].
PBMC RNA isolation, cDNA synthesis and q-
PCR. PBMCs were isolated from whole blood by using BD
Vacutainer Cell Preparation Tubes according to the manufactur-
er’s instructions. PBMC RNA was isolated by using the Qiagen
RNeasy Micro kit (Qiagen, Venlo, Netherlands) and reverse
transcribed using a cDNA synthesis kit (Promega, Leiden,
Netherlands). Standard Q-PCR was performed using SensiMix
real-time PCR reagents (Bioline, London, United Kingdom) and a
Bio-Rad CFX384 machine (Bio-Rad Laboratories BV, Veenen-
daal, the Netherlands). Primer sequences used were chosen based
on the sequences available in PRIMERBANK (http://pga.mgh.
harvard.edu/primerbank/index.html). Q-PCR data were normal-
ized by measuring cycle threshold ratios between candidate genes
and a housekeeping gene, human ribosomal protein LP0, which
was shown to be consistent within PBMCs [24].
Secondary Study Outcomes
Secondary study outcomes were change in plasma cytokine,
glucose, insulin, triglyceride, and free fatty acid concentration after
the high fat challenges. We also studied PBMC immune response
capacity before and after the high fat challenges and we
determined whether abdominal fat distribution of the subjects
influenced the primary and secondary study outcomes.
Plasma cytokines. Plasma samples were analyzed on pre-
formatted arrays (pro-inflammatory panel II, Meso Scale Diag-
nostics, LLC) on a SECTOR Imager 2400 reader (Meso Scale
Diagnostics, LLC) for the measurement of IL1b and TNFa.
Plasma glucose, insulin, triglycerides, free fatty
acids. Immediately after blood was drawn in EDTA-containing
tubes it was centrifuged (7506g, 4uC, 10 min), and plasma was
stored at 280uC until analysis. Plasma FFA concentrations were
analysed by the ACS-ACOD Method (NEFA HR kit, Wako
Chemicals CmbH, Neuss, Germany). Plasma triglyceride and
glucose concentrations were measured using the Dimension
Clinical Chemistry System (Dade Behring Inc, USA). Glucose
was measured by the Synchron LX20 System using hexokinase
and glucose-6-phosphate dehydrogenase (Glucose reagent, Beck-
man Coulter, Fullerton, USA). Insulin concentrations were
measured by enzyme-linked immunosorbent assay (Mercodia,
Uppsala, Sweden).
Serum fatty acid composition in the triglyceride fraction was
determined in pooled samples per group and per high-fat
challenge at 0 h and 4 h and measured by gas-liquid chromatog-
raphy as previously described [22].
Ex-vivo PBMC immune stimulation. PBMC immune
response capacity in the fasted (0 h) condition and 4 h after the
high-fat challenge was tested ex vivo and used as a measure of
PBMC functionality. Ex vivo immune stimulation experiments
were performed in a random subgroup of 13 lean and 15 obese
subjects. Immediately after isolation PBMCs were re-suspended in
RPMI 1640 culture medium with 10% heat-inactivated fetal calf
serum and 1% penicillin and streptomycin. Cells in a concentra-
tion of 2.56104 per ml were stimulated for 2 h at 37uC with 1 ng/
ml lipopolysaccharide (LPS). Subsequently, cells were centrifuged
and supernatants collected and stored at 280uC until analysis.
TNFa produced by the PBMCs was measured in the supernatants
by enzyme-linked immunosorbent assay according to manufac-
turer’s instructions (R&D Systems Europe Ltd, Abingdon, United
Kingdom). LPS-stimulated TNFa production was corrected for
TNFa production in non-stimulated cells.
Body composition and abdominal fat distribution. Body
weight was measured at screening and monitored during the study
period. Body composition was determined on one study day by
air-displacement plethysmography (BodPod; Life Measurement,
Concord, CA) [25]. Abdominal fat distribution, i.e. abdominal
visceral adipose tissue (VAT) and abdominal subcutaneous adipose
tissue (SAT), was measured once during the study period using
magnetic resonance imaging (MRI) in 17 lean, 18 obese and 4
obese diabetic subjects eligible to participate in this measurement.
Axial T1-weighted spin echo images were acquired with a Philips
Gyroscan NT Intera 1.0T scanner using the body coil, with the
subjects in supine position. A total of 14 10-mm-thick slices with
no intersection gap were acquired, with the first slice at the
superior border of the vertebral body of L5, and the remaining
slices superiorly. Images were acquired during breath-hold to
avoid motion artefacts induced by breathing. Images were
retrieved from the scanner using DICOM, and analysed using
HIPPO (version 1.3), an IDL Virtual Machine 6.0-based freeware
designed to quantify adipose tissue areas from MR images [26].
Automatically generated contour lines for SAT and VAT and the
shape of Gaussian curve were manually adjusted by eye, as
necessary. Retroperitoneal adipose tissue was excluded from VAT.
VAT, SAT and VAT/SAT ratios derived from a single slice at the
superior border of the vertebral body of L5 were used in the
analysis.
Statistical Analysis
The statistical packages PASW (version 17.0; SPSS Inc.
Chicago IL) and SAS (version 9.1, SAS Institute Inc. 2004, Cary,
NC, USA) were used for analysis. Differences in baseline
characteristics between subject groups were analysed by analysis
of variance (ANOVA) for single measures (i.e. age, body weight,
body composition) or by linear mixed model for repeated
measures (all other factors that were measured on all three
consecutive study days) and followed by post-hoc LSD tests.
Differences in responses for the different high-fat shakes and
subject groups were analysed by linear mixed model. Delta values
(changes from baseline) were used as dependent variables in the
analysis and baseline values were included as covariables and time
and shake were included as repeated factors in the model. If
statistical significance was found, post-hoc LSD tests were
performed to identify differences between shakes or groups. The
number of obese diabetic subjects included in our trial was lower
than intended, which may influence the chance of finding
significant differences between subject groups. Therefore all
statistical analyses were also performed without including the
obese diabetic subject group. If outcomes differed between both
analyses this is marked in the tables and indicated in the table
footnotes.
The effect of VAT, SAT and VAT/SAT ratio on baseline and
postprandial measures was only investigated within subject groups
because of expected large differences in VAT and SAT between
subject groups due to the predefined BMI categories. Obese
diabetic subjects were excluded for this analysis due to the low
number of subjects that was measured in the MRI scanner. For the
analysis of the effect of body fat distribution VAT, SAT and VAT/
SAT ratio were included as continuous covariables in the linear
mixed model.
Results
Subject Baseline Characteristics
Between September 2009 and December 2009 42 men (18 lean
subjects, 18 obese subjects and 6 obese diabetic subjects) were
Responses to High-Fat Challenges
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recruited and enrolled in the trial (figure 1). Baseline subject
characteristics are displayed in table 2. BMI, bodyfat percentage,
abdominal VAT, abdominal SAT, plasma fasting TAG and
insulin concentrations were significantly higher in obese and obese
diabetic subjects compared with lean subjects. Fasting plasma
glucose concentration was higher in obese diabetic subjects
compared with lean and obese subjects.
Serum Fatty Acid Composition
Baseline values and changes in fatty acid composition of the
TAG fraction in pooled serum samples 4 h after the high-fat
challenge are shown in table S1. The percentage palmitic acid was
1.1-fold higher after the SFA challenge, the percentage oleic acid
was 1.6-fold higher after the MUFA challenge and the percentage
DHA was 9.5-fold higher after the n-3 PUFA challenge, reflecting
the composition of the shakes.
Primary Study Outcomes
PBMC gene expression. Gene expression levels at baseline
(fasting state) were not different between the subject groups.
Changes in expression of PDK4, LDLr, IL8 and MCP1
expression were depending on the type of fat in the challenge.
The MUFA challenge induced a lower decrease in PDK4
expression at 2 h (p,0.001) if compared with the other
challenges. The MUFA and n-3 PUFA challenge induced a
higher increase in MCP1 and IL8 expression at 4 h (p,0.05)
compared with the SFA challenge.
The high-fat challenge altered expression of several metabolic
genes and inflammation-related genes (table S2). Changes in
expression of the metabolic genes ABCA1 and LDLr and the
inflammation-related genes IL1b and MCP1 depended on
whether the subjects were lean, obese or obese diabetic.
Changes in expression of ABCA1 and LDLr were less
pronounced for obese and obese diabetic subjects (p,0.05)
compared with lean subjects. Differences between groups in
expression changes of IL1b and MCP1 were most likely due to
higher increases of expression of these genes in obese diabetic
subjects compared with lean and obese subjects, since the effects
were not significant when obese diabetic subjects were excluded
from analysis.
There were no interaction effects between subject groups and
shakes for the measured genes.
Figure 1. CONSORT flow diagram.
doi:10.1371/journal.pone.0041388.g001
Table 2. Baseline characteristics of the participants.
Lean
(n =18)
Obese
(n=18)
Obese diabetic
(n=6)
Age (y) 61.865.9 62.663.2 64.264.6
BMI (kg m22) 23.860.8 32.463.01 33.563.31
Body fat (%) 21.965.7 38.265.21 39.965.11
VAT (cm2)2 102640 2316751 2156311
SAT (cm2)2 163652 3506991 3836421
VAT/SAT ratio2 0.6460.20 0.6860.24 0.5760.12
TAG (mmol/L) 1.560.5 2.160.92 2.061.02
FFA (mmol/L) 0.5160.21 0.5160.13 0.5860.11
Insulin (mmol/L) 6.162.8 13.466.62 13.367.82
Glucose (mmol/L) 5.260.4 5.560.4 7.261.02
Values are expressed as mean 6 standard deviation. Abbreviations: Free fatty
acids (FFA), Triglycerides (TAG), Subcutaneous Adipose Tissue (SAT), Visceral
adipose tissue (VAT).
1Significantly different (p,0.05) from lean subjects.
2For VAT, SAT en VAT/SAT ratio n = 17 for lean subjects, n = 18 for obese
subjects and n = 4 for obese diabetic subjects.
doi:10.1371/journal.pone.0041388.t002
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Secondary Study Outcomes
Plasma cytokines. Fasting plasma IL1b concentration was
higher in obese diabetic subjects compared to lean and obese
subjects (table 3). Changes in plasma concentrations of IL1b
varied according to the type of fat in the challenge and whether
the subjects were lean, obese or obese diabetic. Plasma concen-
trations of TNFa after the challenge were different between
groups, with lower TNFa concentrations in lean compared with
obese and obese diabetic subjects (p,0.05). TNFa responses over
time were not different between the groups. Changes in plasma
IL1b concentration differed among subject groups, however, the
group and shake effects for IL1b were probably mainly due to the
deviating IL1b responses of some obese diabetic subjects, since the
shake and shake*group effects were not significant when the obese
diabetic subjects were excluded from the analysis.
PBMC immune response capacity. Fasting levels and
changes in PBMC immune response capacity after the high-fat
challenges, measured as ex vivo LPS-stimulated TNFa production
of PBMCs, were neither depending on the type of fat in the
challenge, nor depending on the metabolic risk profile of the
subjects (table 3). However, TNFa production was significantly
lower (P,0.001) 4 h after the high-fat challenge compared with
the fasting state.
Plasma FFA, TAG, insulin and glucose
responses. Changes in FFA, TAG, insulin and glucose
concentration after the different high-fat challenges in the subject
groups are depicted in table 4 and figure 2. Concentrations of
FFA, TAG, insulin and glucose were changed after all three high-
fat challenges. The magnitude of the changes in these metabolites
was depending on the type of fat consumed. The high MUFA
challenge caused a higher total TAG response (p,0.001) and a
reduced drop in FFA concentrations at 2 h (p,0.05) compared
with the SFA and n-3 PUFA challenge. The n-3 PUFA challenge
caused a less pronounced increase in insulin concentration
(p,0.01) at 2 h compared with SFA and MUFA.
The changes in TAG, FFA, insulin and glucose concentrations
were also different between lean, obese and obese diabetic
subjects. For TAG response an interaction effect between group
and shake (p = 0.048) was observed, meaning that the postprandial
TAG response was different for lean, obese and obese diabetic
subjects and depending on the type of high-fat shake consumed.
Abdominal fat distribution. Within the group of lean
subjects and within the group of obese subjects there was no
significant influence of abdominal fat distribution (i.e. VAT, SAT
or VAT/SAT) on changes in plasma FFA, TAG, insulin or
glucose concentrations, changes in PBMC gene expression, or
changes in cytokine concentrations in response to the high-fat
challenges.
Discussion
This study shows that in response to a high-fat challenge, the
expression of the metabolic genes ABCA1, LDLr and inflammatory
genes IL1b and MCP1 differed between lean, obese and obese
subjects with diabetes. Moreover, plasma TAG, FFA, insulin and
glucose concentrations after the challenge differed between
subjects with distinct metabolic phenotypes. Comparison of
responses to high-fat challenges high in SFA, MUFA or n-3
PUFA showed that high MUFA induced the most pronounced
response, especially for TAG.
The decrease in ABCA1 and the increase in LDLr expression in
lean subjects in response to the challenge were comparable with
observations in lean subjects in earlier studies performed by us and
others [18,27]. The novel observation of a less pronounced change
in expression of these cholesterol metabolism genes in obese and
obese diabetic subjects may reflect a less optimal metabolic
adaptation response of their PBMCs to the challenge. This might
be caused by lower lipid uptake by the cells and/or lower
activation of gene expression in response to high-fat intake,
possibly due to lowered sensitivity of the cells to lipids. Changes in
expression of ABCA1 and LDLr in response to a high-fat challenge
might thus be considered as potential markers of health status.
The change in expression of the inflammatory genes IL1b and
MCP1 in response to the challenge was also different between
groups, mainly due to larger increases in obese diabetic subjects,
and not in obese subjects. We might consider these gene
expression changes as indicators of a more severe metabolic
phenotype; however we should interpret the study outcomes for
the diabetic group with caution, since only a low number of
diabetic subjects were included in the study. The greater change in
IL1b expression in obese diabetic subjects was not reflected in
plasma IL1b concentrations. This could be explained by the fact
that IL1b is also produced by other cells than PBMCs. The low
power to detect significant effects in the small obese diabetic
subject group with high variation in cytokine response may also
play a role.
PBMC gene expression responses to the challenges were also
depending on the type of fat consumed. The n-3 PUFA and
MUFA challenge induced higher increases in MCP1 and IL8
expression compared to the SFA challenge. This is in line with
findings from a previous study showing that acute high n-3 PUFA
intake induced a pro-inflammatory PBMC gene expression profile
[18]. A possible explanation for this induction is that unsaturated
fatty acids are more prone to oxidation than SFA and might
induce more oxidative stress and in turn affect inflammatory
status. However, no differences in expression changes of hypoxia
inducible factor (HIF1a) were seen among the fat challenges
(unpublished data). Another explanation may be that palmitic
acid, which is generally more regularly consumed, poses less stress
to PBMCs resulting in lower expression changes of inflammation
genes than high doses of oleic acid or DHA. A high-fat palm oil
shake may thus be less suitable to acutely challenge the system
compared to shakes containing unsaturated fats.
After all high-fat challenges PBMC immune response capacity
was reduced, but whether this reduction is an indication of lower
inflammatory status or diminished cell immune functioning cannot
be distinguished. Moreover, an effect of circadian rhythm on
PBMCs cannot be excluded. Since PBMC immune response
capacity was not different between subject groups, this ex vivo test
after a challenge may not be a sensitive indicator for differences in
health status.
The secondary study outcomes, plasma TAG, FFA, insulin and
glucose concentrations after the challenge, clearly differed between
subjects with distinct metabolic phenotypes. The differential
changes in TAG and insulin concentrations in lean, obese and
obese diabetic subjects are in line with results from postprandial
studies showing higher TAG and insulin responses in obese and
diabetic subjects after high-fat consumption [4,7,8,28,29]. We
consider the differential changes in TAG and insulin in obese and
obese diabetic subjects as a reflection of reduced cellular
adaptation capacity to respond to a high-fat challenge.
The plasma metabolic responses to the challenges were also
depending on the type of fat consumed. Comparison of responses
to high in SFA, MUFA or n-3 PUFA challenges showed that high
MUFA induced the most pronounced response, especially for
TAG. The TAG-raising effect after a MUFA challenge was more
pronounced in obese and obese diabetic subjects, suggesting that
acute high MUFA intake might be a stronger metabolic challenge
Responses to High-Fat Challenges
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41388
T
a
b
le
4
.
C
h
an
g
e
s
in
m
e
ta
b
o
lic
p
ar
am
e
te
rs
in
p
la
sm
a
o
f
le
an
su
b
je
ct
s
(n
=
1
8
),
o
b
e
se
su
b
je
ct
s
(n
=
1
8
)
an
d
o
b
e
se
d
ia
b
e
ti
c
su
b
je
ct
s
(n
=
6
)
at
2
h
an
d
4
h
af
te
r
h
ig
h
fa
t
sh
ak
e
co
n
su
m
p
ti
o
n
.
S
F
A
sh
a
k
e
M
U
F
A
sh
a
k
e
n
-3
P
U
F
A
sh
a
k
e
M
a
in
e
ff
e
ct
s
In
te
ra
ct
io
n
e
ff
e
ct
s
0
h
D
2
h
D
4
h
0
h
D
2
h
D
4
h
0
h
D
2
h
D
4
h
g
ro
u
p
ti
m
e
sh
a
k
e
G
ro
u
p
*t
im
e
G
ro
u
p
*s
h
a
k
e
S
h
a
k
e
*t
im
e
T
A
G
(m
m
o
l/
L)
Le
an
1
.5
3
6
0
.4
9
0
.6
4
6
0
.4
0
0
.4
8
6
0
.4
8
1
.3
7
6
0
.4
1
0
.9
1
6
0
.4
7
1
.4
1
6
1
.0
0
1
.5
0
6
0
.5
0
0
.3
3
6
0
.3
0
0
.7
8
6
0
.5
8
0
.8
8
9
,
0
.0
0
1
,
0
.0
0
1
0
.0
0
2
0
.0
4
8
,
0
.0
0
1
O
b
e
se
2
.0
7
6
0
.9
9
0
.5
8
6
0
.4
0
0
.7
8
6
0
.6
1
2
.1
3
6
1
.0
6
1
.1
4
6
0
.6
8
2
.2
8
6
1
.1
8
1
.9
8
6
0
.7
8
0
.3
0
6
0
.2
6
0
.7
7
6
0
.4
5
O
b
e
se
d
ia
b
e
ti
c
2
.1
7
6
1
.1
6
0
.3
0
6
0
.1
4
0
.8
0
6
1
.2
1
1
.9
2
6
0
.9
3
1
.0
8
6
0
.4
9
2
.4
7
6
1
.2
1
2
.0
5
6
1
.2
1
0
.3
8
6
0
.1
3
1
.0
5
6
0
.4
9
FF
A
(m
m
o
l/
L)
Le
an
0
.5
1
6
0
.2
1
2
0
.2
1
6
0
.1
9
2
0
.0
4
6
0
.2
2
0
.4
9
6
0
.2
0
2
0
.1
0
6
0
.1
8
0
.0
3
6
0
.2
3
0
.5
5
6
0
.2
3
2
0
.2
5
6
0
.2
1
2
0
.0
3
6
0
.1
7
0
.0
0
4
,
0
.0
0
1
0
.0
0
2
0
.0
1
6
0
.3
9
0
0
.0
0
2
O
b
e
se
0
.4
8
6
0
.1
0
2
0
.1
8
6
0
.1
2
0
.1
1
6
0
.1
1
0
.5
0
6
0
.1
5
2
0
.0
9
6
0
.1
6
0
.0
8
6
0
.1
6
0
.5
4
6
0
.1
5
2
0
.2
1
6
0
.1
1
0
.0
6
6
0
.1
6
O
b
e
se
d
ia
b
e
ti
c
0
.5
3
6
0
.1
3
2
0
.2
0
6
0
.1
2
0
.0
7
6
0
.2
0
0
.5
8
6
0
.1
3
2
0
.0
8
6
0
.1
8
0
.1
2
6
0
.2
8
0
.6
2
6
0
.0
5
2
0
.1
2
6
0
.2
5
0
.0
9
6
0
.2
1
In
su
lin
(m
m
o
l/
L)
Le
an
6
.5
2
6
2
.5
5
3
.0
8
6
3
.7
7
2
1
.8
2
6
2
.0
8
5
.8
0
6
3
.3
8
2
.7
3
6
3
.8
8
1
.0
0
6
3
.9
8
6
.0
2
6
2
.5
5
2
0
.0
2
6
3
.7
7
2
1
.6
4
6
2
.5
6
0
.0
1
7
,
0
.0
0
1
,
0
.0
0
1
0
.0
2
8
0
.8
0
8
,
0
.0
0
1
O
b
e
se
1
3
.5
2
6
7
.4
0
6
.5
9
6
9
.6
0
2
1
.6
7
6
3
.3
3
1
2
.8
1
6
5
.2
4
4
.3
9
6
6
.6
2
1
.7
9
6
6
.0
7
1
3
.9
1
6
7
.2
5
2
.3
3
6
5
.8
7
2
2
.0
4
6
3
.0
9
O
b
e
se
d
ia
b
e
ti
c
1
2
.6
6
6
7
.5
0
8
.8
5
6
4
.6
4
0
.0
3
6
1
.4
0
1
3
.5
7
6
8
.7
8
7
.4
3
6
3
.7
1
2
.6
6
6
5
.3
0
1
3
.7
9
6
8
.4
9
1
.2
7
6
4
.2
6
2
0
.7
5
6
4
.2
0
G
lu
co
se
(m
m
o
l/
L)
Le
an
5
.1
9
6
0
.3
9
2
0
.3
0
6
0
.3
5
2
0
.4
0
6
0
.2
1
5
.1
7
6
0
.3
5
2
0
.2
9
6
0
.3
1
2
0
.0
8
6
0
.2
8
5
.2
9
6
0
.5
3
2
0
.4
2
6
0
.3
9
2
0
.3
3
6
0
.2
5
0
.8
7
2
,
0
.0
0
1
0
.0
0
2
,
0
.0
0
1
0
.6
6
0
,
0
.0
0
1
O
b
e
se
5
.5
0
6
0
.4
1
2
0
.1
6
6
0
.4
8
2
0
.4
3
6
0
.3
9
5
.5
3
6
0
.4
3
2
0
.1
8
6
0
.3
2
2
0
.3
1
6
0
.2
8
5
.5
4
6
0
.2
8
2
0
.4
3
6
0
.3
8
2
0
.5
2
6
0
.3
3
O
b
e
se
d
ia
b
e
ti
c
7
.2
2
6
0
.9
4
0
.4
7
6
0
.6
7
2
1
.5
2
6
0
.4
8
7
.1
7
6
1
.0
4
2
0
.0
3
6
1
.1
4
2
0
.6
8
6
0
.8
5
7
.2
3
6
1
.2
5
2
0
.4
8
6
1
.4
3
2
1
.0
0
6
0
.6
8
V
al
u
e
s
ar
e
e
xp
re
ss
e
d
as
m
e
an
6
SD
.
Sa
tu
ra
te
d
fa
tt
y
ac
id
(S
FA
),
m
o
n
o
u
n
sa
tu
ra
te
d
fa
tt
y
ac
id
(M
U
FA
),
p
o
ly
u
n
sa
tu
ra
te
d
fa
tt
y
ac
id
(P
U
FA
),
Fr
e
e
fa
tt
y
ac
id
s
(F
FA
),
T
ri
g
ly
ce
ri
d
e
s
(T
A
G
).
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
4
1
3
8
8
.t
0
0
4
Responses to High-Fat Challenges
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e41388
for subjects with a metabolic risk phenotype. It should be further
investigated whether the plasma TAG response to a MUFA
challenge could be used as a marker to detect small differences in
health status in subjects with more comparable phenotypes.
The MUFA challenge may have been the most challenging for
the biological system because it contained almost exclusively oleic
acid (83% of total fat) while the other shakes contained a mixture
of fatty acids. Our test shakes were not reflecting habitual meal
intake, but used as a metabolic challenge test. However, because
habitual intake of fish n-3 PUFA is very low we prepared an n-3
PUFA shake consisting of a mixture of palm oil and 55 gr fish oil,
a well-tolerated dose in a former study at our group [18]. In the
Figure 2. Changes in plasma metabolic parameters at 2 h and 4 h after high-fat shake consumption. Mean (6 SEM) changes in plasma
triglyceride (A), free fatty acid (B), insulin (C) and glucose (D) concentrations of lean subjects (n = 18), obese subjects (n = 18) and obese diabetic
subjects (n = 6) after consumption of 3 different shakes, enriched in saturated fatty acids (SFA, line with squares), monounsaturated fatty acids (MUFA,
dotted line with triangles) or n-3 polyunsaturated fatty acids (n-3 PUFA, dashed line with circles). Different letters indicate significant differences
(p,0.05) between shakes at a given time.
doi:10.1371/journal.pone.0041388.g002
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latter study, consumption of an n-3 PUFA shake containing this
high dose of 55 gr n-3 PUFA and no palm oil, decreased
expression of LXR signalling genes in PBMCs of young, lean men
when compared to consumption of an SFA shake with 55 gr butter
fat. Although we gave a higher total fat load, we observed no
expression differences for these genes. This may be due to
differences in fat types (palm oil vs. butter), shake composition,
sampling time (4 h vs 6 h) or age of the subjects.
Remarkably, our n-3 PUFA shake induced a less pronounced
increase in insulin concentration compared with the other shakes.
Only few other studies have reported acute insulin-lowering effects
of n-3 PUFA intake [15,30]. Peak insulin concentrations are
reached normally between 0–2 h after a meal [4,19,31], but we
lack data for these early time points. n-3 PUFA intake might have
caused an earlier insulin peak resulting in lower insulin concen-
trations at later time points.
The amount of VAT, SAT or the VAT/SAT ratio did not
influence the response to a high-fat challenge within subject
groups. Although the number of subjects per group might have
been too small to detect a significant effect of fat distribution, it is
also arguable whether high VAT is strongly affecting metabolic
health; some studies did find an effect of VAT, mainly on TAG
response [9,32,33], but others suggested that liver fat might be a
more sensitive determinant of metabolic health [34,35]. VAT
comprises only about 10% of total body fat, which might also be a
reason that no VAT-dependent effect was seen.
In our study we monitored different aspects of the response to
high-fat challenges, i.e. plasma metabolites, inflammatory proteins,
PBMC gene expression and immune cell functioning. We were
able to detect differential changes in expression of metabolic
parameters and certain genes between the selected subject groups
differing in BMI and health status. However, for identification of
small differences between responses of subjects that are pheno-
typically more similar, more sensitive monitoring of the response is
needed. Whole genome transcriptome, proteome or metabolome
profiling tools could be used for more extensive characterization of
the challenge response. As shown in previous studies, extensive
profiling could identify subtle changes of genes, proteins or
metabolites in pathways and clusters [14,36]. The combination of
challenge tests and extensive profiling may reveal changes in
health status at a very early stage [37].
In conclusion, of the three fat types studied most pronounced
changes were seen for the high oleic sunflower oil (MUFA).
Therefore this fat type seems the most promising challenge to test
metabolic response capacity. We identified several genes expressed
in PBMCs and plasma metabolic measures that were differently
responding to a high-fat challenge in subjects with distinct
metabolic risk phenotypes. These potential markers are likely
candidates to be further tested and used in high-fat challenge tests
to define metabolic response capacity of subjects.
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